Becauseenhanced P-gp-mediated efflux is common to most MDR cancer types,we envision that these results could inspire the design of immunotherapeuticdrugs with mechanisms of action that are broadly enhanced in MDR cancersthat have failed treatment or acquired resistance to chemotherapeutics. The gene discussed is PGP; the disease is cancer.